Literature DB >> 20031067

Real-time PCR for diagnosis of oculoglandular tularemia.

Max Maurin, Bernard Castan, Nathalie Roch, Brieuc Gestin, Isabelle Pelloux, Alexandra Mailles, Christophe Chiquet, Pascal Chavanet.   

Abstract

Entities:  

Mesh:

Year:  2010        PMID: 20031067      PMCID: PMC2874363          DOI: 10.3201/eid1601.090793

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


× No keyword cloud information.
To the Editor: Oculoglandular tularemia accounts for 3%–5% of all diagnosed tularemia cases (). We report the diagnosis of this disease in 2 patients in France by real-time PCR. Patient A, a 43-year-old woman, was referred in October 2006 to the infectious disease department of Auch Hospital (Auch, France). She had a fever (39°C) and severe conjunctivitis of the right eye that had evolved over 2 weeks despite administration of amoxicillin/clavulanate. The patient lived in a rural area endemic for tularemia and had regular contact with dogs and ring doves. She remembered harvesting mushrooms in a nearby forest a few days before onset of clinical symptoms. Physical examination showed a hyperemic and painful right conjunctiva, enlarged (0.5–1.5 cm in diameter) and tender preauricular and submandibular lymph nodes, and cellulitis of the right hemiface. Her condition rapidly improved after she received doxycycline and gentamicin. Patient B, a 42-year-old woman, was referred in October 2008 to the infectious disease department of Dijon University Hospital (Dijon, France) for intermittent fever (38.5°C) and swollen left-sided pretragal and cervical lymph nodes, which had evolved for 3 weeks despite administration of amoxicillin, followed by pristinamycin and prednisone, and ciprofloxacin for 7 days. The patient remembered being scratched on the left hand by her dog several weeks earlier; the scratch healed spontaneously. She had recently walked in a nearby forest that was endemic for tularemia. Physical examination showed enlarged (2–3 cm in diameter), tender lymph nodes and bilateral conjunctivitis. Her condition improved after doxycycline therapy, but the pretragal lymph nodes were removed surgically in late November 2008 because of suppuration and necrosis. Ofloxacin was administered until January 2009 because of persistence of inflammation in cervical lymph nodes and suppuration with skin fistulization in the pretragal region. Diagnostic investigations (Table) conducted at Grenoble University Hospital included serologic tests (microagglutination and indirect immunofluorescent antibody assay by using locally prepared Francisella tularensis subsp. holarctica antigen), culture, and 2 real-time PCRs. These PCRs were specific for insertion sequence ISFtu2 or the Tul4 protein–encoding gene of Francisella sp. and used previously described primers, probes, an amplification protocol (), and a LightCycler 2.0 apparatus (Roche, Meylan, France). We tested 5 μL of DNA extracted from clinical samples by using the QIAamp DNA Mini kit (QIAGEN, Hilden, Germany). Three negative controls (DNA-free water) and 1 positive control (DNA extracted from the F. tularensis subsp. holarctica LVS strain) were used for each PCR.
Table

Characteristics of the 2 patients in the study and test results for tularemia, France*

CharacteristicPatient APatient B
Age, y/sex43/F42/F
Blood leukocyte count at admission, cells/mm321,6004,000–10,000
Blood granulocyte count at admission, cells/mm317,9002,000–8,000
C-reactive protein level at admission, mg/L
51
39
Serologic test results for Francisella tularensis
First serum sample, d616
Microagglutination titer<20<20
Immunofluorescent IgM titer<20<20
Immunofluorescent IgG titer<20<20
Second serum sample, d9039
Microagglutination titer80160
Immunofluorescent IgM titer160320
Immunofluorescent IgG titer
160
320
Real-time PCR result for ISFtu2 and tul4, sample (cycle threshold for each test, respectively)Positive, conjunctival discharge (32.4 and 34.9)Positive, pretragal lymph node (22.3 and 24.5)
Francisella sp. culture, samplePositive, conjunctival dischargeNegative
Francisella subsp. identificationsubsp. holarcticasubsp. holarctica

*Ig, immunoglobulin.

*Ig, immunoglobulin. Seroconversion was found between acute-phase and convalescent-phase serum samples from both patients. A conjunctival cotton swab sample from patient A and pretragal lymph node suppuration and biopsy samples from patient B were positive for F. tularensis by both real-time PCRs. A Francisella sp. strain was isolated from the conjunctival discharge from patient A at Auch Hospital and Grenoble Hospital laboratories. Cultures were grown in a BioSafety Level 3 laboratory at Grenoble University Hospital because results of both PCRs were positive. Cultures of specimens from patient B were negative. Both patients were infected with an F. tularensis subsp. holarctica strain. Infection was identified by PCR amplification and sequencing of the 16S rRNA gene (fD1 and rP2 primers) and the intergenic spacer region (FTitsFw 5′-ACCACGGAGTGATTCATGACTG-3′ and FTitsRv 5′-TCTCAATTGATTTCTCTTCCTAAGG-3′ primers) from the strain isolated from patient A and directly from the lymph node biopsy specimen from patient B. Conjunctival inoculation of F. tularensis usually occurs by contact when a contaminated finger comes into contact with the eyes, e.g., after handling of an infected animal or tick (,), but the source of infection often remains undetermined, as for our 2 patients. Symptoms are not specific and correspond to Parinaud oculoglandular syndrome (). Reported complications include keratitis, occasional corneal perforation, and lymph node suppuration; tonsillitis, cellulitis in nearby skin tissue, retinitis, erythema nodosum, and progression to systemic disease occur less frequently (–). A specific microbiologic diagnosis is needed for appropriate treatment because many microorganisms can cause Parinaud oculoglandular syndrome and clinical symptoms are not specific (,). Fluoroquinolones are now considered first-line treatment for tularemia; β-lactam antimicrobial agents are not effective (). Oculoglandular tularemia is a painful disease with a short incubation period (3–5 days), and results of serologic tests of acute-phase samples are often negative (,). Isolation of F. tularensis is difficult and hazardous to laboratory personnel (,). PCR-based techniques may enable a more rapid diagnosis (,,). Heating clinical samples before testing prevents laboratory-acquired infections. We report the use of real-time PCR for detection of F. tularensis from a conjunctival swab specimen. Many clinical laboratories are now equipped with this technology. Transport conditions of clinical samples (4°C, no transport medium, 24–48 h) are not restrictive. When compared with PCR, real-time PCR does not require post-PCR processing, enabling a faster turn-around time. Oculoglandular tularemia is a rare but underestimated disease. Real-time PCR detection of F. tularensis DNA from conjunctival swab suspensions now provides a rapid, noninvasive, sensitive, and specific diagnosis of oculoglandular tularemia. This assay enables early establishment of specific antimicrobial drug therapy and poses no risk of infection for laboratory staff.
  10 in total

1.  Erythema nodosum revealing oculoglandular tularemia.

Authors:  R Peter; T Banyai
Journal:  Dermatology       Date:  2001       Impact factor: 5.366

2.  Typhoidal tularemia.

Authors:  D M Marcus; A R Frederick; T Hodges; J D Allan; D M Albert
Journal:  Arch Ophthalmol       Date:  1990-01

3.  Oculoglandular tularemia.

Authors:  T L Steinemann; M R Sheikholeslami; H H Brown; R W Bradsher
Journal:  Arch Ophthalmol       Date:  1999-01

4.  Tickborne oculoglandular tularemia: case report and review of seasonal and vectorial associations in 106 cases.

Authors:  R L Guerrant; M K Humphries; J E Butler; R S Jackson
Journal:  Arch Intern Med       Date:  1976-07

5.  Comparative analysis of PCR versus culture for diagnosis of ulceroglandular tularemia.

Authors:  A Johansson; L Berglund; U Eriksson; I Göransson; R Wollin; M Forsman; A Tärnvik; A Sjöstedt
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

6.  Parinaud's oculoglandular syndrome attributable to an encounter with a wild rabbit.

Authors:  S Thompson; L Omphroy; T Oetting
Journal:  Am J Ophthalmol       Date:  2001-02       Impact factor: 5.258

7.  Diagnostic approaches for oculoglandular tularemia: advantages of PCR.

Authors:  Todor Kantardjiev; Plamen Padeshki; Ivan N Ivanov
Journal:  Br J Ophthalmol       Date:  2007-05-02       Impact factor: 4.638

8.  Oculoglandular syndrome caused by Francisella tularensis.

Authors:  S A Halperin; T Gast; P Ferrieri
Journal:  Clin Pediatr (Phila)       Date:  1985-09       Impact factor: 1.168

9.  Development of a multitarget real-time TaqMan PCR assay for enhanced detection of Francisella tularensis in complex specimens.

Authors:  Jessica L Versage; Darlena D M Severin; May C Chu; Jeannine M Petersen
Journal:  J Clin Microbiol       Date:  2003-12       Impact factor: 5.948

Review 10.  New approaches to diagnosis and therapy of tularemia.

Authors:  Arne Tärnvik; May C Chu
Journal:  Ann N Y Acad Sci       Date:  2007-04-27       Impact factor: 5.691

  10 in total
  3 in total

1.  A case of tularemia after an endurance run in a non-endemic region.

Authors:  R Meckenstock; A Therby; A Le Monnier; D Khau; S Monnier; B Pangon; A Greder-Belan
Journal:  Infection       Date:  2012-10-17       Impact factor: 3.553

2.  Establishment of SYBR green-based qPCR assay for rapid evaluation and quantification for anti-Hantaan virus compounds in vitro and in suckling mice.

Authors:  Fei Wei; Jin-lin Li; Jia-xin Ling; Liang-Jun Chen; Ning Li; Yuan-Yuan Liu; Fan Luo; Hai-Rong Xiong; Wei Hou; Zhan-Qiu Yang
Journal:  Virus Genes       Date:  2012-10-10       Impact factor: 2.332

3.  Treatment of tularemia in pregnant woman, France.

Authors:  Charlotte Dentan; Patricia Pavese; Isabelle Pelloux; Sandrine Boisset; Jean-Paul Brion; Jean-Paul Stahl; Max Maurin
Journal:  Emerg Infect Dis       Date:  2013-06       Impact factor: 6.883

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.